Ratings for Chemours (NYSE:CC) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.29, a high estimate of $27.00, and a low estimate of $19.00. Highlighting a 9.02% decrease, the current average has fallen from the previous average price target of $24.50.

Deciphering Analyst Ratings: An In-Depth Analysis

The standing of Chemours among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Chemours's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Chemours analyst ratings.

All You Need to Know About Chemours

Chemours's Financial Performance

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Negative Revenue Trend: Examining Chemours's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.27% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.

Net Margin: Chemours's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.57%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Chemours's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.27%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Chemours's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.11%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Chemours's debt-to-equity ratio surpasses industry norms, standing at 7.21. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.